Good morning. Good morning, my name is Kim Kelderman, and thanks, Jefferies, for inviting us. Got an exciting story to tell, and I see my time started ticking, so let's get right into it. We're Bio-Techne, and before we start, I want to draw your attention to the safe harbor statement. You can find a edition of this on the bio-techne.com website under the Investor Relations chapter. We talk about our mission. At Bio-Techne, we want to improve the quality of life by catalyzing advances in science and medicine. And we want to do so to get closer to our vision, in which we together unlock the possibilities of sciences. And before I talk about our progress towards that vision, I want to talk about something foundational, which is ESG. I'm proud to announce that we have published our third corporate sustainability report, and that there's tremendous progress being made. We used to monitor our main site mainly, but now also monitor all our sites for greenhouse gas emissions. From a social point of view, we have a very diverse and inclusive workplace, and my commitment is to make that even more so a diverse workplace. I think diversity is a true competitive advantage long term, and it's certainly one of our one of the things we're proud of, but also one of the things we further wanna drive. Also fun to see and very honorable and a good team-building exercise, that our employees are always active in our communities and do charitable activities. From a governance point of view, we have a fantastic board with several scientific, as well as, people with fantastic business expertise backgrounds. If we get into the company overview, headquartered in Minneapolis, 3,100 people, and last year, $1.1 billion. That's where I get to that circle there in the middle. 10% of the revenue is related to instruments, 7 + 2 related to services and royalties, 81% related to consumables. And out of that 81%, 10% of that are consumables directly related to the instruments, so cartridges and so on. Now, the company reports in two segments, Protein Sciences Segment, we call it PSS, as well as the Diagnostics and Genomics Segments, I call it DGS. In PSS, we have three business units that are fully focused on core products, such as proteins, antibodies, and immunoassays, and there are also two growth verticals. We call it growth verticals because we've acquired assets that are then in a specific vertical market in which we believe we can grow very fast. There we have cell and gene therapy and proteomic analytical instrumentation. On the diagnostics and genomics side, we have core products in reagents and controls and bulk, bulk chemistries, but two growth verticals, one around spatial biology and one around liquid biopsy. So how do revenues break out amongst those growth verticals is on this slide, and you see in the top left here, 74% for the PSS segment, the lion's share, and 26% of the revenues are related to diagnostics and genomics. On the inner circle, you can see how that breaks out per segment. You see on the left side, nine o'clock, the core with 44%, the core that is the core in protein sciences, so 44% of Bio-Techne's revenue. But you see that cell and gene therapy is growing fast, so now 7%, and the proteomic analytical instrumentation is 23%. On the DGS side, 12% related to core, but then we have liquid biopsy with 5% and spatial biology with 9%. And those growth verticals obviously are outpacing the core, so you see that those percentages are getting larger. If you think about it, right now, 56% of the company is related to some sort of core business, and the balance is related to these fast-growing vertical markets. If you look at the end markets, 50% related to pharma, biopharma, 13% distributors, mainly APAC and China, and then we have diagnostics and academics, just around 20% each. The geographies, lion's share in the US, 60%, 24% in Europe, 10% in China and 6% in Asia. Now, if you look at the end markets that we address, I talked about the core. Core market addresses $6 billion, and it's growing mid-single digits. We've always outpaced that core a little bit, and therefore, our historical growth is 7.7%, and we enjoy a 10% market share. But the exciting part there comes with the four growth verticals I just mentioned. Here you see those markets laid out. They're all substantially substantial markets. They're all growing more than double digits, and we have been able to keep up and/or even outpace that market growth. And you can see from the market share that we still have plenty of headspace to continue that growth and capture market share in those growth verticals. Now, a theme that I wanted to touch on on this slide is that there are mega trends which we take into consideration in order to pick those growth verticals. Because you could argue, like, how do you come up with those growth verticals? Doesn't make sense, but they do, and that's because of this pyramid. You see in the middle that we believe in, in general, you know, overhead is always expensive, so automation, making things automated with less manual interaction, is a mega trend in our minds. Multiomics. So we used to look only at DNA, then we started focusing on RNA, and now proteomics is absolutely in fashion. But we believe that multiomics, meaning looking at several of those modalities, is going to be the winning approach. Using AI, making sense of large data models, creating precision medicine, where medicine and therapies are precise for certain individuals or certain diseases. And of course, at the end of the day, we all wanna age healthily. In the meantime, on the right-hand side of the pyramid, you see the regulatory journey, right? So products are commonly used in research, and therefore they have the label of research use only, right? You tinker around, and at some point you find the markers or a therapy that you want to bring to market, and you find that out and validate that during your translational development. And then eventually you come up with a diagnostic or a treatment, right? And there, the ingredients, as well as, of course, the therapy, have to be fully validated, meaning you will have to submit to the FDA or any other authority around the world. And for that, you need qualified, validated GMP ingredients. We as a company have really focused on the fact that we have RUO reagents, but we also create that journey so that we can go with the customer along this, this development phase, and make sure that our reagents are having the ability to be GMP certified. On the left-hand side, you see our core products that of course play in this, in this, research area. But then you see that we have the product lines, the verticals, very nicely aligned with that journey all the way to, to treatments, and again, to boost our, our healthy aging. On the next slide, you can see the strategy that we deploy underneath. The core products, of course, we want to leverage those by going to market directly with our proteins and antibodies, but we also leverage those in the growth verticals. Each and every one of those growth verticals uses those core products that we have, that took us 47 years to put together, and therefore pulls them through. They're in margin, but also it makes these instruments look better because we have high-quality reagents. Yes, we wanna grow and leverage the core, but we want to make sure that we go into and capitalize on high-potential markets, and that's the growth, the pillar that I just talked about with those four growth verticals in there. We also want to continue to acquire. We have acquired 19 companies over the last 10 years, and we did it in a healthy pace. And what's also very important, we have also integrated really well, 'cause even if you buy a good asset, but you don't know how to integrate, that also not ideal, but we have been able to do both: pick the right assets and integrate. In the meantime, innovation, making sure that if you have a nice business unit yourself or if you have acquired another company, you need to make sure that these technologies talk and that you get the synergies out of it, and therefore we are focused and also very good, I feel, on the innovation side to bring things together. Last but not least, the customer is centric to us, and we wanna make sure that we continue to have a great relationship with the customer, understand what problems they wanna solve, make sure that they are making progress as fast as possible. And we also are boosting our e-commerce platform so that it's easy to order our products. Now, of course, to do all these verticals, you need a great crew, and our Bio-Techne family is handpicked, and we are really proud of our culture and the way we make progress in a fun way. We go to the next slide. I quickly describe our core products. As you see here, we have proteins, antibodies, small molecule, molecules, immunoassays for various platforms, and diagnostic controls and calibrators. Those also go into various platforms from third parties. A great library of products, but at the end of the day, you would ask, like: So why have you been outpacing market there a little bit? How have you been able to be competitive? And it's really a combination of these things here. Choice. We have about 6,000 proteins, right? 400,000 antibodies, a huge menu of small molecules, also very important, and a large portfolio of immunoassays, and there is a tremendous confidence in those products. And again, I mentioned the most famous brand is R&D Systems, which has been around for 47 years, is gold standard. And we achieve that by following stringent quality standards. We test every lot, and we make sure that there is a lot-to-lot consistency, high bioactivity, so it's high-quality biologics, and we build our antibodies from the best-in-class proteins. And therefore, you see our customers, we are by far have the most publications around our materials. In the meantime, we continue to innovate. We innovate on our processes and our factories and the way we make stuff, but also using AI to have smart designs of our different products, specifically proteins. And then very important for us is the cross-divisional collaboration. So the divisions that have these core products in there, they need to work together with these growth verticals, because the growth verticals will look better, grow faster, utilizing these ingredients. So we have an internal, very efficient machine to collaborate together. Now, if I look at our growth verticals, the very first one I'll talk about, or here's the whole group, and I just talk about the mechanism where we have 47 years of core products, where there are fantastic efforts and know-how that went into designing these portfolios over the last 47 years. And we also utilize these core products in these four verticals I'd mentioned earlier. Let me take the first one as an example, antibodies. So antibodies go into the workflows for ProteinSimple, right? For the proteomic analysis. In the meantime, the spatial biology, we acquired a platform, COMET, from Lunaphore, and that looks at proteins, and for that, you use antibodies. So the same antibodies that sit in our freezers, already designed and manufactured, get pulled through on that platform. Now, and last but not least, we will also launch GMP antibodies in line with that megatrend of following the regulations, right? And those GMP antibodies will also get pulled through into the cell and gene therapy vertical, for example. So now you see how our secret sauce works together and how we have very efficient verticals with nifty acquisitions that have the ability to capture market share in those vast fast-growing markets, but that they all hinge on and hand in hand with these core products. The next slide, I'll quickly show you our instrumentation portfolio. We have instruments around Simple Western, biologics, Simple Plex, and also a cell sorter with the brand of Namocell. These are all based on the fundamental that you want to automate, clunky and/or labor-intense processes, and therewith make them automated and make sure that you can, that you can rapidly get to a very consistent, repeatable result, right? That's the premise under these instrumentations. The next slide, a little bit of a double click on how we increase the market in which we can place those systems. You know, the real driver is the increase of applications, and across those three platforms, you see that we have expanded their utilization in cell and gene therapy, mainly. Two things I want to mention that are outside of cell and gene therapy. There on the left-hand side, you see biologics. We have launched a couple of quarters ago, the Maurice Flex, which is the top, top end of our line, and the Maurice Flex can also do fractionation and directly communicate with your mass spec, which is also historically a very clunky process, but now fully automated. On the right-hand side, you see the Simple Plex, and that achieved its ISO 13485 certification, and that is again in line with that megatrend, that you should be able to use your instruments and your reagents higher up the pyramid, if it comes to regulatory approvals. And this instrument is now usable by partners that want to go into a diagnostic and near patient. It has a turnaround time of 90 minutes, so, so it's now enabled, and in the press releases, you can see that we have our first assay, our first collaboration with this, Ella in ophthalmic assays, and, we have a pipeline of DX applications for this instrument and enter that market soon. Cell and gene therapy, here, same, same trajectory of regulatory increases. You see that in cell culture, we have RUO media, we have RUO small molecules, but you go to the regen medicine, and you see that we have, different versions, GMP media, GMP proteins, and all the stuff you would need in the regenerative medicines field. In immune cell therapy, most of our activity has been around the G-Rex. The G-Rex, I'll talk about, but what you put in there are GMP-qualified materials, and it is typically related to GMP media, cytokines, chemokines, and various other small molecules that you would utilize in this G-Rex. The G-Rex is a product from Wilson Wolf. We own 20% of Wilson Wolf right now. End of calendar year 2027, we will own 100% of this company. And the nifty part is that it has this small bioreactor, really, that from the bottom, in a patented way, gets oxygen into it, so the cells can breathe and grow. And then, of course, you would need to create the right broth around it, which is based upon our portfolio of these core reagents I talked about. And that creates... So this case, it's not an instrument that pulls through our core reagents, but it's basically this consumable that pulls through our core reagents. And with that, you can grow T cells faster than any other solution, and since it's one patient, one container, typically, you know, you can scale this up pretty rapidly. You know, a normal small incubator, you can put already more than 10 of these G-Rexes in there. And of course, you can put as many incubators as you want to go against the wall, and very scalable, unlike other solutions. Spatial biology, a growth vertical we have invested in heavily just because we think it's going places. Of course, it's already $5 billion addressable market. We have ACD in this business unit, which is basically an 11-year-old company that created 50,000 RNA markers to study RNA very precisely, single cell, single molecule resolution. Then last year, we acquired Lunaphore. Here you see this, the instrument, it's called COMET. The real cool thing about this COMET is that you can put four samples at the same time, and you can use a normal slide with a normal cover slip instead of having to transfer your tissue into something that is in a different workflow. Here, you can use your standard sample, and then the machine is fully automated. So it does its hybridization, it does the RNAs, the RNA phase, it does the protein phase, and what comes out is a beautiful image with software that's on board that shows you a true multi-omic work. So it shows you everything on the protein side as well as on the RNA side, which is very, very unique. We will launch an assay that makes this really easy to run in the coming months, and yeah, we're very excited about this solution. And it's fully automated, so you can run it overnight. Next morning, your images are ready and no manual interaction needed in between. What does that give us? We have antibodies, and the Lunaphore on the left-hand side, you see a couple of modalities related to protein analysis, and then you see from the RNAscope point of view, we have all kinds of different lengths or types of RNAs you can interrogate. And in the meantime, in the middle there, you see this little human. We can do over 200 species, and then all kinds of types of organs, all types of tissue, fresh frozen, FFPE, anything you really like. So amazing flexibility on this instrument. And of course, that is essential to look at autoimmune diseases as well as gene therapy. So it fits really nicely with our portfolio. We go to the molecular diagnostics business. You can see current products, right? We have 12 products on market, two of those IVD approved, and then you see in the CLIA setting, we have ExoDx Prostate test. This came with the ExosomeDx acquisition, and we've talked about it quarterly, how nicely this prostate test is growing. If you go one level lower, you can see our pipeline, and you see that the pipeline have more little names in there on the left than the right, and that's because those are the columns for, on the left top, screening, and screening typically means many patients, right? And all the way on the top right, you see monitoring. That means somebody got diagnosed with something, you're on a certain treatment, and now you monitor how the patient is doing. And that means fewer patients, but more often testing, right? So we like the two outsides of this matrix, and therefore, you see that our R&D is mainly in those two areas. We focus on single gene markers on the right-hand side, where we will launch in the coming months, new assays in a kitted format that are exosome-based. For larger screening tests, we feel that it's better to get partnerships. On the right-hand side, you see for transplant rejection, we've partnered with Thermo Fisher Scientific and utilize their channel, and they have signed an agreement to bring that test to market. Therefore, you see at the bottom, our channels. We have urology channel, of course, for the prostate test, clinical laboratory channel for all the other tests that we sell to laboratories, and then Thermo for the transplant channel. Why do we believe exosomes are so important? Exosomes are those little bubbles that come popping out of cells, and they're designed for intercellular communication. The nice thing is that compared to circulating tumor cells and/or cell-free DNA, they have all information on board. It's protected because that's what they're actually designed for. They shed those exosomes daily, even early stages of their lives, and therefore, there's an early abundance. And early abundance is important for early detection, which we all know the quicker you can detect something, the better the outcome is, right? You can enrich them, so you can fish them out of your sample. They're very stable, and the outside of the exosome is the same as the originating cell, so you can know where it's coming from. The graph on the right, I won't explain it too much, but basically it shows that if you use exosomes in your experiment, the sensitivity and specificity goes up. Well, that doesn't surprise because eventually at the bottom there, you can see that a healthy cell sheds thousands of exosomes. Any cell, by the way, also unhealthy cells, and that for cell-free DNA, you will only get two copies in your sample after the cell dies, so it's much harder to detect. So we are big fans, big believers in the exosome platform. If I go to one of our signature dishes, that's M&A. We've done 19 acquisitions in the last 10 years. You can see that it has a very strong impact on our revenues, and that is because most of these acquisitions we use to build those four verticals. And these four verticals are outgrowing overall markets. And here you can see it one more time on my very last slide. We have really strong brands in our core products. We go to market with those core products with our direct sales force. We also sell those core products in those four verticals. The proteomics analytics, you see we did an acquisition, more or less of $500 million of CyVek as well as ProteinSimple. We have a real nice portfolio there, fast-growing, and of course, that pulls through those reagents. Same with cell and gene therapy, where the pull-through really comes from the G-Rex. We spent $374 million in the initial acquisitions. We also built GMP facilities for over $15 million organically, and then we will pay another $1 billion for Wilson Wolf. So that is what it took for us organically and inorganically to build that vertical. Then we have the spatial biology, where we did the Lunaphore instrumentation acquisition and the ACD reagents. Then liquid biopsy is a combination of the ExosomeDx and the Asuragen kitting and consumable channels into the laboratories. And that overall gives us the profile that we really, really like, which is that we can outperform market by 500 to 1,000 basis points. Our margins are targeted to be between 35% to 40%, if it comes to the operating margins, and of course, high teens EPS, and that is the exciting part of our company. That's why employees are enjoying working there, our customers are enjoying working with us, and hopefully, investors also enjoy following us and being part of the Bio-Techne story. Thank you very much.